With Biohaven's Nurtec ODT Off And Running, Focus Turns To What Is Next

 
• By Jessica Merrill

The oral CGRP inhibitor for migraine generated solid second quarter results as the company expanded to the prevention setting. Several new potential growth drivers are moving through the pipeline.

Building Blocks
Biohaven is building out a long-term growth strategy • Source: Alamy

More from Neurological

More from Therapy Areas